ACC 2020 The VICTORIA trial demonstrated that therapy with the sGC stimulator vericiguat reduced the primary endpoint in HFrEF patients with worsening HF condition compared to placebo.

A composite outcome of CV death or HF/renal failure rehospitalization through day 180 occurred more frequently in acute HF patients with lower LVEF.

A register study shows that initiation of sacubitril/valsartan treatment in real-world hospitalized HFrEF patients is safe, and these patients more frequently receive low starting doses than outpatients.

Low urinary sodium excretion during the first 6h after diuretic initiation is associated with lower urinary output in the first 24h and all-cause mortality in patients with acute heart failure.

Prof. Solomon gives a comprehensive overview of the PARAGON-HF trial and presents results of an analysis of combined data of the PARADIGM-HF and PARAGON-HF trials. With question to test your knowledge.

Sacubitril-valsartan was well tolerated in stable HFrEF patients in a real-world population. Target dose was achieved in most patients and was linked to down-titration of diuretic dose.

Three phenogroups were identified in TOPCAT HFpEF patients, ranging from a low-risk group with mild symptoms to a high-risk obese, diabetic group with advanced symptoms that responded well to spironolactone.

This pilot RCT in acute decompensated HF patients showed that empagliflozin did not result in reduction of primary endpoints, but did reduce a combined endpoint of worsening HF, rehospitalization for HF or death compared to placebo.

The EVALUATE-HF trial was set up to study the effects of sacubitril/valsartan treatment on cardiac and hemodynamic mechanisms, to look into how these may explain the observed clinical benefits.

This prospective registry study of a real-world cohort of elderly HFrEF patients showed that sacubitril/valsartan was safe and effective, even in those >80 years.

Prof. Pieske gives a broad overview of heart failure with mid range ejection fraction, including prevalence, etiolgies and treatment options.

Results of the EMPERIAL-Reduced and EMPERIAL-Preserved trials were announced, which both showed no benefit in exercise ability with use of empagliflozin in HFrEF and HFpEF patients, respectively.